Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors

Biochemical and Biophysical Research Communications

Volumn 330, Issue 4, 2005, Pages 1205-1212

  Lee, Hyun Wook ^a   Lee, Seung Hyun ^a   Lee, Hae Won ^a   Ryu, Yeon Woo ^a   Kwon, Myung Hee ^b   Kim, Yong Sung ^a  

^a Ajou University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Death decoy receptors; Death receptors; Homomeric and heteromeric interactions; SPR; TRAIL

Indexed keywords

CELL RECEPTOR; DEATH DECOY RECEPTOR 1; DEATH DECOY RECEPTOR 2; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; MONOMER; OLIGOMER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE; QUANTITATIVE ANALYSIS; RECEPTOR AFFINITY; SOLUBILITY; SURFACE PLASMON RESONANCE;

EID: 17044382532     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.03.101     Document Type: Article

References (31)

1. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, C. Blackie, L. Chang, A.E. McMurtrey, A. Hebert, L. DeForge, I.L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, and R.H. Schwall Safety and antitumor activity of recombinant soluble Apo2 ligand J. Clin. Invest. 104 1999 155 162
2. H.N. LeBlanc, and A. Ashkenazi Apo2L/TRAIL and its death and decoy receptors Cell Death Differ. 10 2003 66 75
3. A. Almasan, and A. Ashkenazi Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy Cytokine Growth Factor Rev. 14 2003 337 348
4. S.R. Wiley, K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, and C.A. Smith Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673 682
5. G. Pan, K. O'Rourke, A.M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and V.M. Dixit The receptor for the cytotoxic ligand TRAIL Science 276 1997 111 113
6. G. Pan, J. Ni, G. Yu, Y.F. Wei, and V.M. Dixit TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling FEBS Lett. 424 1998 41 45
7. J.P. Sheridan, S.A. Marsters, R.M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C.L. Gray, K. Baker, W.I. Wood, A.D. Goddard, P. Godowski, and A. Ashkenazi Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors Science 277 1997 818 821
8. M.A. Degli-Esposti, W.C. Dougall, P.J. Smolak, J.Y. Waugh, C.A. Smith, and R.G. Goodwin The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain Immunity 7 1997 813 820
9. G. Pan, J. Ni, Y.F. Wei, G. Yu, R. Gentz, and V.M. Dixit An antagonist decoy receptor and a death domain-containing receptor for TRAIL Science 277 1997 815 818
10. T.S. Griffith, C.T. Rauch, P.J. Smolak, J.Y. Waugh, N. Boiani, D.H. Lynch, C.A. Smith, R.G. Goodwin, and M.Z. Kubin Functional analysis of TRAIL receptors using monoclonal antibodies J. Immunol. 162 1999 2597 2605
11. X.D. Zhang, A. Franco, K. Myers, C. Gray, T. Nguyen, and P. Hersey Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma Cancer Res. 59 1999 2747 2753
12. X.D. Zhang, X.Y. Zhang, C.P. Gray, T. Nguyen, and P. Hersey Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria Cancer Res. 61 2001 7339 7348
13. S.S. Cha, B.J. Sung, Y.A. Kim, Y.L. Song, H.J. Kim, S. Kim, M.S. Lee, and B.H. Oh Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity J. Biol. Chem. 275 2000 31171 31177
14. S.G. Hymowitz, H.W. Christinger, G. Fuh, M. Ultsch, M. O'Connell, R.F. Kelley, A. Ashkenazi, and A.M. de Vos Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5 Mol. Cell 4 1999 563 571
15. J. Mongkolsapaya, J.M. Grimes, N. Chen, X.N. Xu, D.I. Stuart, E.Y. Jones, and G.R. Screaton Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation Nat. Struct. Biol. 6 1999 1048 1053
16. G. Zhang Tumor necrosis factor family ligand-receptor binding Curr. Opin. Struct. Biol. 14 2004 154 160
17. D.W. Seol, and T.R. Billiar Cysteine 230 modulates tumor necrosis factor-related apoptosis-inducing ligand activity Cancer Res. 60 2000 3152 3154
18. P. Schneider Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins Methods Enzymol. 322 2000 325 345
19. N. Sreerama, and R.W. Woody Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set Anal. Biochem. 287 2000 252 260
20. J.G. Emery, P. McDonnell, M.B. Burke, K.C. Deen, S. Lyn, C. Silverman, E. Dul, E.R. Appelbaum, C. Eichman, R. DiPrinzio, R.A. Dodds, I.E. James, M. Rosenberg, J.C. Lee, and P.R. Young Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J. Biol. Chem. 273 1998 14363 14367
21. S.G. Hymowitz, M.P. O'Connell, M.H. Ultsch, A. Hurst, K. Totpal, A. Ashkenazi, A.M. de Vos, and R.F. Kelley A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL Biochemistry 39 2000 633 640
22. Y.J. Jang, K.S. Park, H.Y. Chung, and H.I. Kim Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities Cancer Lett. 194 2003 107 117
23. S.S. Cha, M.S. Kim, Y.H. Choi, B.J. Sung, N.K. Shin, H.C. Shin, Y.C. Sung, and B.H. Oh 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity Immunity 11 1999 253 261
24. A. Truneh, S. Sharma, C. Silverman, S. Khandekar, M.P. Reddy, K.C. Deen, M.M. McLaughlin, S.M. Srinivasula, G.P. Livi, L.A. Marshall, E.S. Alnemri, W.V. Williams, and M.L. Doyle Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor J. Biol. Chem. 275 2000 23319 23325
25. F.K. Chan, H.J. Chun, L. Zheng, R.M. Siegel, K.L. Bui, and M.J. Lenardo A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling Science 288 2000 2351 2354
26. F.C. Kischkel, D.A. Lawrence, A. Tinel, H. LeBlanc, A. Virmani, P. Schow, A. Gazdar, J. Blenis, D. Arnott, and A. Ashkenazi Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8 J. Biol. Chem. 276 2001 46639 46646
27. J.H. Naismith, T.Q. Devine, B.J. Brandhuber, and S.R. Sprang Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor J. Biol. Chem. 270 1995 13303 13307
28. R.M. Siegel, J.K. Frederiksen, D.A. Zacharias, F.K. Chan, M. Johnson, D. Lynch, R.Y. Tsien, and M.J. Lenardo Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations Science 288 2000 2354 2357
29. F.C. Kischkel, D.A. Lawrence, A. Chuntharapai, P. Schow, K.J. Kim, and A. Ashkenazi Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5 Immunity 12 2000 611 620
30. I. Remy, I.A. Wilson, and S.W. Michnick Erythropoietin receptor activation by a ligand-induced conformation change Science 283 1999 990 993
31. R.F. Kelley, K. Totpal, S.H. Lindstrom, M. Mathieu, K. Billeci, L. Deforge, R. Pai, S.G. Hymowitz, and A. Ashkenazi Receptor-selective mutants of Apo2L/TRAIL reveal a greater contribution of DR5 than DR4 to apoptosis signaling J. Biol. Chem. 2004